Vaping-associated lung injury causing organizing pneumonia: A case report
ABSTRACT: A 64-year-old male with no previous history of lung disease presented with intermittent pleuritic chest pain and shortness of breath. The patient had a 20 pack-year smoking history but had recently quit and had started using electronic cigarettes (e-cigarettes). An initial CT scan of his chest revealed right lower lobe opacification with associated ground glass, and over the next 6 months he developed bilateral opacifications in a centrilobular fashion. Infection, connective tissue disease, and cardiac disease were ruled out through preliminary investigations and bronchoscopy. Given the concerns over malignancy, an open lung biopsy was performed and the pathology results indicated an organizing pneumonia. A multidisciplinary team discussion favored a diagnosis of lung injury secondary to inhaled agents or a drug reaction. The patient was found to meet the diagnostic criteria for e-cigarette, or vaping, product use–associated lung injury (EVALI) based on his history of vaping, the presence of bilateral pulmonary infiltrates, and the absence of infection. His symptoms abated with cessation of e-cigarette use, and further intervention was not required. This case of inhalational lung disease secondary to nicotine use through electronic delivery systems raises concerns about the rapid uptake and growth of vaping, especially among adolescents, and the need for product regulation.
The case of a 64-year-old male diagnosed with organizing pneumonia after switching from smoking combustible cigarettes to using e-cigarettes. This report highlights the manifestations of e-cigarette–related lung damage as well as a need to increase public awareness about the harmful effects of vaping.
Electronic cigarettes (e-cigarettes) are a type of nicotine delivery system that consists of a cartridge that contains a liquid, an atomizer (heating element), and a battery. Commonly used liquids contain various substances, including nicotine, cannabinoids such as tetrahydrocannabinol (THC), flavoring, and additives such as glycerol and propylene glycol. Use of these aerosolized devices (colloquially termed vaping) has risen substantially among the Canadian population, in particular among younger individuals. In 2017, 15.4% of Canadians aged 15 years and older (4.6 million) reported having tried an e-cigarette, and 2.9% (~863 000) had used an e-cigarette in the previous 30 days. Among adolescents in grades 8, 10, and 12 in the United States, vaping prevalence more than doubled in each of the three grades from 2017 to 2019. In 2019, it was estimated that more than 25% of students in the 12th grade in the United States had vaped during the previous 30 days, while 12% of students stated that they vaped daily. Multiple case series were published in autumn 2019 when hospitalizations linked to lung disease and electronic nicotine delivery systems increased throughout the United States. These cases are now known collectively as e-cigarette, or vaping, product use–associated lung injury (EVALI).[4,5] As of November 2019, there have been more than 2800 cases of EVALI in North America, which have displayed a heterogeneous pattern of lung pathology that includes organizing pneumonia, acute respiratory distress syndrome, acute eosinophilic pneumonia, lipoid pneumonia, diffuse alveolar damage, diffuse alveolar hemorrhage, and hypersensitivity pneumonitis. Given the increased incidence and potential severity of EVALI, renewed focus has been placed on the pathophysiology and corresponding health effects of vaping, and on the need for product regulation.
In July 2017, a 64-year-old male with a 20 pack-year smoking history presented to his family physician with complaints of intermittent pleuritic chest pain and shortness of breath for several months. He had quit smoking combustible cigarettes 4 years previously and had transitioned to an e-cigarette, with increasing daily use. He had used a single variety of nicotine fluid with no THC. He was a retired office manager and had not traveled recently or had environmental exposures, such as home renovations or living with pets. His medical history included hypertension, diabetes, and dyslipidemia, and his medications included metformin, pantoprazole, candesartan, indapamide, and atorvastatin.
An X-ray of the patient’s chest in July 2017 revealed no abnormalities [Figure 1], but a CT scan with contrast in November 2017 revealed right middle and lower lobe opacifications with associated ground glass opacity [Figure 2]. Given the clinical and radiographic findings, a broad differential diagnosis that included atypical infections, inflammatory conditions, hemorrhage, and malignancy was considered, and a respirology referral was made.
The patient’s cardiovascular and respiratory exam showed no abnormalities, and there was no peripheral stigmata of chronic lung disease. Pulmonary function tests done shortly after the patient’s initial CT scan demonstrated an FEV1 of 2.6 litres (90% predicted) and FVC of 3.7 litres (95% predicted). The ratio of FEV1 to FVC was low normal at 0.70, and no reversibility was seen with bronchodilators. The patient’s bloodwork revealed a CBC with no eosinophilia, and his tests for C-reactive protein, antinuclear antibodies, rheumatoid factor, and antineutrophil cytoplasmic antibodies were all negative, as were tests for hepatitis B and C, and HIV.
Because of concerns about malignancy given the patient’s smoking history and the initial images obtained, a CT scan of his chest was repeated in January 2018 [Figure 3]. Airspace opacities within the right middle lobe and right lower lobe were seen to have persisted and to have increased in size relative to the November 2017 scan. Many of the lesions had peripheral consolidation with central ground glass opacity, known radiographically as the reversed halo sign (atoll sign), a finding specific to organizing pneumonia. Similar patchy airspace opacities had also developed in the left upper and lower lobes. The changing appearance of the patient’s lungs on the CT scans over a short interval narrowed the differential diagnoses to include organizing pneumonia, eosinophilic pneumonia, vasculitis, pulmonary lymphoma, and alveolar hemorrhage.
After the patient’s second CT scan, a bronchoscopy was undertaken to obtain tissue samples by wash, brush, and biopsy. Endobronchial anatomy, including the right lower lobe, showed no abnormalities upon inspection. Bronchoalveolar lavage of the RB6 bronchus (superior segment of the right lower lobe) demonstrated numerous pulmonary macrophages and a moderate number of mixed inflammatory cells. Cultures for bacteria and fungi were negative as were results from a respiratory viral panel, and no antigen was found for Pneumocystis jiroveci. Tissue biopsies of the RB9 and RB10 segments showed intra-alveolar macrophages, mild interstitial inflammation, and mild fibrosis.
Given the diagnostic uncertainty and persistent changes in the right lower and left upper lobes on imaging from November 2017 and January 2018, another chest X-ray [Figure 4] and additional CT images [Figure 5] were obtained in May 2018 to facilitate a wedge resection by thoracic surgery. The new CT scan showed wider areas of consolidation, coalescing lesions in the right lower and left upper lobes, and increasing amounts of associated ground glass opacification. The patient underwent a thoracoscopy and wedge resection of the superior segment of the left lower lobe; pathology from that biopsy showed evidence of cicatricial organizing pneumonia [Figure 6]. Interestingly, after the patient ceased e-cigarette use, his symptoms completely resolved over a matter of weeks and were gone prior to his May 2018 CT scan and wedge resection despite radiographic progression. In consultation with the chest radiologists and pathology department at Vancouver General Hospital, lung injury secondary to inhaled agents, a drug reaction, or connective tissue disorders were thought to be the most likely diagnoses given the distinctly centrilobular localization and the odd radiologic waxing and waning over 6 months. He did not require the use of corticosteroids, although he continues to require follow-up with serial CT scans.
The patient presented with respiratory complaints consisting of pleuritic pain and intermittent shortness of breath and underwent serological testing, spirometry, and bronchoscopy. Persistent radiographic changes, including bilateral consolidations and associated ground glass opacities, were seen over a 6-month period, and pathology results from a wedge resection of the left lower lobe indicated an organizing pneumonia. Classically, organizing pneumonia has been categorized as cryptogenic or secondary, with secondary causes being related to another lung pathology (vasculitis, hypersensitivity pneumonitis, eosinophilic pneumonia, interstitial lung diseases) or lung injury (infection, drug toxicity, inhalation of toxic gas, aspiration of gastric contents, organ transplant, radiotherapy). The patient underwent extensive testing to rule out secondary causes of his clinical and radiographic features. The consensus diagnosis by a multidisciplinary team favored a drug reaction or inhalation exposure that caused an organizing pneumonia. A search of the online database Pneumotox for information on the patient’s medications indicated that atorvastatin can cause a drug-related interstitial lung disease; however, a large cohort analysis of more than 6000 individuals published in 2013 showed no link between statins and interstitial lung disease. Therefore, other inhalation exposures were considered, with particular focus on the patient’s use of e-cigarettes.
A Wisconsin and Illinois cohort series proposed diagnostic criteria for EVALI, which include use of an e-cigarette or related product in the previous 90 days, lung opacities on chest X-rays or CT scan, exclusion of infection, and absence of other likely alternatives such as heart failure or connective tissue disease. In a recent Centers for Disease Control and Prevention report, more than 2800 cases of EVALI and more than 60 related deaths were described. The most common symptoms were cough, shortness of breath, and fatigue; other symptoms included fever, chest pain, weight loss, nausea, and diarrhea. Most of what we know about toxic inhalation syndromes comes from studies of patients with high levels of exposure in occupational settings or from house fires.
At present, there are many questions about the pathophysiology of EVALI. The aerosols produced by e-cigarettes are highly heterogeneous, which makes in vitro models difficult to study. The composition of the aerosol depends on the ingredients in the liquid, the electrical characteristics of the heating element, the temperature reached, and the characteristics of the wick. E-cigarette liquids generally consist of glycerol (vegetable glycerin), propylene glycol, and nicotine. In Layden and colleagues’ case series of persons who vaped and developed EVALI, 60% used a combination of THC and nicotine, 27% used THC alone, and 11% used nicotine alone. Vaping fluids containing THC have been formulated with oils, such as vitamin E acetate, whereas most nicotine-only products are mixed with propylene glycol and glycerin.[11,12] Vitamin E has been implicated in the bronchoalveolar-lavage fluid in EVALI patients. Flavoring agents such as diacetyl, which is commonly found in e-fluids containing nicotine, have been shown to cause bronchiolitis obliterans and other severe respiratory diseases in exposed plant workers. However, even though several large cohort studies were published in 2019, no single constituent was common to all cases. Butt and colleagues reviewed lung biopsies from 17 patients, all of whom had a history of vaping and were clinically suspected of having vaping-associated lung injury. In all cases, histopathological findings showed patterns of acute lung injury, including acute fibrinous pneumonitis, diffuse alveolar damage, or organizing pneumonia, as seen in the case discussed in this article.
Currently, there is no standardized treatment for EVALI. Initial treatment usually focuses empirically on more common causes of lung injury, such as infection or underlying lung disease. If EVALI is suspected, most patients are treated with supportive management, including hospital admission and supplemental oxygen if indicated and critical care if progression to acute respiratory distress syndrome occurs. Findings from case series have suggested that patients with worsening hypoxia despite other treatment efforts may benefit from a trial of corticosteroids, but evidence is limited. It is suggested that patients be followed in the community until their symptoms resolve and imaging indicates improvement.
Given our patient’s vaping history, investigation results, and radiographic findings, a presumptive diagnosis of EVALI was made. His significant clinical improvement with cessation of e-cigarette use also makes EVALI the most likely explanation for his clinical syndrome.
A 64-year-old male with no previous history of lung disease underwent investigations after presenting with intermittent pleuritic chest pain and shortness of breath. A multidisciplinary team discussed the laboratory, imaging, and pathology results and concluded that a drug reaction or inhalation exposure had caused organizing pneumonia. The patient’s symptoms abated with cessation of his e-cigarette use and further intervention was not required. Based on a history of vaping, the presence of bilateral pulmonary infiltrates, and the absence of both infection and a likely alternative diagnosis, the patient was found to meet the diagnostic criteria for EVALI.
This case and others reported recently demonstrate a link between electronic nicotine delivery systems and chemically induced acute lung injury. This case also highlights questions about the mechanism of toxicity and the unpredictable clinical course of EVALI. Given the dramatic rise in e-cigarette use, especially among adolescents, continued efforts should be made to increase public awareness of the harmful effects of e-cigarettes.
This article has been peer reviewed.
1. Gotts JE, Jordt SE, McConnell R, Tarran R. What are the respiratory effects of e-cigarettes? BMJ 2019;366:l5275.
2. University of Waterloo. Tobacco use in Canada. 2017. https://uwaterloo.ca/tobacco-use-canada/e-cigarette-use-canada.
3. Snyder TD, de Brey C, Dillow SA. Digest of education statistics. Washington, DC: National Center for Education Statistics, Institute of Education Statistics; 2018.
4. Miech R, Johnston L, O’Malley PM, et al. Adolescent vaping and nicotine use in 2017–2018—U.S. national estimates. N Engl J Med 2019;380:192-193.
5. Layden JE, Ghinai I, Pray I, et al. Pulmonary illness related to e-cigarette use in Illinois and Wisconsin—final report. N Engl J Med 2020;382:903-916.
6. Chatham-Stephens K, Roguski K, Jang Y, et al. Characteristics of hospitalized and nonhospitalized patients in a nationwide outbreak of e-cigarette, or vaping, product use–associated lung injury—United States, November 2019. MMWR Morb Mortal Wkly Rep 2019;68:1076-1080.
7. Maturu VN, Agarwal R. Reversed halo sign: A systematic review. Respir Care 2014;59:1440-1449.
8. Baque-Juston M, Pellegrin A, Leroy S, et al. Organized pneumonia: What is it? A conceptual approach and pictorial review. Diagn Interv Imaging 2014;95:771-777.
9. Saad N, Camus P, Suissa S, Ernst P. Statins and the risk of interstitial lung disease: A cohort study. Thorax 2013;68:361-364.
10. Dinaker C, O’Connor GT. The health effects of electronic cigarettes. N Engl J Med 2016;375:1372-1381.
11. Blount BC, Karwowski MP, Shields PG, et al. Vitamin E acetate in bronchoalveolar-lavage fluid associated with EVALI. N Engl J Med 2020;382:697-705.
12. Burstyn I. Peering through the mist: Systematic review of what the chemistry of contaminants in electronic cigarettes tells us about health risks. BMC Public Health 2014;14:18.
13. Kreiss K, Gomaa A, Kullman G, et al. Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant. N Engl J Med 2002;347:330-338.
14. Butt YM, Smith ML, Tazelaar HD, et al. Pathology of vaping-associated lung injury. N Engl J Med 2019;381:1780-1781.
Dr Baumann is a respirology fellow at the University of British Columbia. Dr Churg is a professor of pathology at the University of British Columbia and a pathologist at Vancouver General Hospital. Dr Aboulhosn is a respirologist at Island Health and a clinical instructor in the Division of Respiratory Medicine at the University of British Columbia.
Brett Baumann, MD, Andrew Churg, MD, FRCPC, Kewan Aboulhosn, MD, FRCPC. Vaping-associated lung injury causing organizing pneumonia: A case report. BCMJ, Vol. 62, No. 8, October, 2020, Page(s) 268-271 - Clinical Articles.
Above is the information needed to cite this article in your paper or presentation. The International Committee
of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally
accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
About the ICMJE and citation styles
The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.
An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.
BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:
- Only the first three authors are listed, followed by "et al."
- There is no period after the journal name.
- Page numbers are not abbreviated.
For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org
The patient should have been asked about the source of his e-cigarette liquids or if he had mixed his own liquids. Counterfeit products and noncommerical ingredients may have been a source of contaminated liquids. Also note that the EVALI lung injuries occur quickly, not over a long period of e-cigarette use.
The US Centers for Disease Control and Prevention states that 82% of cases (66% male) were amongst users of illegal tetrahydrocannabinol (THC) cartridges. This percentage is expected to be an under-report because underage patients (and adults as well) may not have admitted to their illegal activities. During the fall of 2019 the US Food and Drug Administration shut down 44 illegal THR online vape sites with Operation Vapor Lock (https://www.fda.gov/news-events/press-announcements/fda-dea-seize-44-web...). Subsequently, the number of new cases plummeted (Harnett et al., 2019, CDC website). With new cases down to near zero and having identified vitamin-E acetate – a thickening agent in illegal/black market THC liquids consumed with vapourizers – as the culprit of the outbreak, the CDC stopped reporting on EVALI on 25 February 2020. Furthermore, the CDC recommends that “adults using nicotine-containing e-cigarette, or vaping, products as an alternative to cigarettes should not go back to smoking.”
US Centers for Disease Control and Prevention website on EVALI
Hartnett, K.P., Kite-Powell, A., Patel, M.T., Haag, B.L., Sheppard, M.J., Dias, T.P., King, B.A.,
Melstrom, P.C., Ritchey, M.D., Stein, Z. and Idaikkadar, N. (2019), “Syndromic surveillance for ecigarette, or vaping, product use–associated lung injury”, New England Journal of Medicine, Vol. 382 No. 8, pp. 766-772.
O'Leary, R., & Polosa, R. (2020). Tobacco harm reduction in the 21st century. Drugs and Alcohol Today. Open access: https://www.emerald.com/insight/content/doi/10.1108/DAT-02-2020-0007/ful...